Beneficial
Effects of High Dietary Fiber Intake in Patients
with Type 2 Diabetes Mellitus
The New England Journal of Medicine
Manisha Chandalia, M.D.,
Abhimanyu Garg, M.D., Dieter Lutjohann, Ph.D., Klaus von Bergmann,
M.D., Scott M. Grundy, M.D., Ph.D., and Linda J. Brinkley, R.D.
ABSTRACT
Background
The effect of increasing the intake of dietary fiber
on glycemic control in patients with type 2 diabetes mellitus
is controversial.
Methods
In a randomized, crossover study, we assigned 13 patients
with type 2 diabetes mellitus to follow two diets, each
for six weeks: a diet containing moderate amounts of
fiber (total, 24 g; 8 g of soluble
fiber
and 16 g of insoluble fiber),
as recommended by the American Diabetes Association
(ADA), and a high-fiber diet (total,
50 g; 25 g of soluble fiber
and 25 g of insoluble fiber)
containing foods not fortified with fiber
(unfortified foods). Both diets, prepared in a research
kitchen, had the same macronutrient and energy content.
We compared the effects of the two diets on glycemic
control and plasma lipid concentrations.
Results
Compliance with the diets was excellent. During the sixth
week of the high-fiber diet, as compared with
the sixth week of the ADA diet, mean daily preprandial
plasma glucose concentrations were 13 mg per deciliter
(0.7 mmol per liter) lower (95 percent confidence interval,
1 to 24 mg per deciliter [0.1 to 1.3 mmol per liter];
P=0.04) and mean daily urinary glucose excretion was
1.3 g lower (median difference, 0.23 g; 95 percent
confidence interval, 0.03 to 1.83; P=0.008). The high-fiber
diet also lowered the area under the curve for 24-hour plasma
glucose and insulin concentrations, which were measured every
two hours, by 10 percent (P=0.02) and 12 percent (P=0.05),
respectively. The high-fiber diet reduced
plasma total cholesterol concentrations by 6.7 percent
(P=0.02), triglyceride concentrations by 10.2 percent
(P=0.02), and very-low-density lipoprotein cholesterol concentrations
by 12.5 percent (P=0.01).
Conclusions
A high intake of dietary fiber, particularly
of the soluble type, above the level
recommended by the ADA, improves glycemic control,
decreases hyperinsulinemia, and lowers plasma lipid
concentrations in patients with type 2 diabetes.
Source Information
From the Department of Internal
Medicine (M.C., A.G., S.M.G., L.J.B.) and the Center for Human
Nutrition (A.G., S.M.G.), University of Texas Southwestern Medical
Center, Dallas; the Department of Veterans Affairs Medical Center,
Dallas (M.C., A.G., S.M.G.); and the Department of Clinical Pharmacology,
Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany (D.L.,
K.B.).
|
|